Joaquín Martínez-López

8PUBLICATIONS
25CO-AUTHORS
Haematological tumoursDiagnostic radiographyMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 31, 2025
Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.

Alberto Blanco-Sánchez, Rosa Ayala, Gonzalo Carreño-Tarragona

|May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.

Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven

|Aug 21, 2023
Regulation of miRNA expression by α4β1 integrin-dependent multiple myeloma cell adhesion.

Yaiza Rodríguez-García, Mónica Martínez-Moreno, Lola Alonso

|May 19, 2023
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.

Rosa Ayala, Rafael Alonso Fernández, Valentín García-Gutiérrez

|Jul 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

Paul G Richardson, Arnon Nagler, Dina Ben-Yehuda

|Jun 06, 2020
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.

Enrique M Ocio, Cristina Motlló, Paula Rodríguez-Otero

Pageof 2

Frequent Collaborators

3 joint publications

Rosa Ayala Diaz

2 joint publications

Rafael Alonso Fernández

1 joint publications

Sjoerd J F Hermans

1 joint publications

Thomas Pabst